[go: up one dir, main page]

AU1804499A - Inhibition of tumor growth by macrophage intervention - Google Patents

Inhibition of tumor growth by macrophage intervention

Info

Publication number
AU1804499A
AU1804499A AU18044/99A AU1804499A AU1804499A AU 1804499 A AU1804499 A AU 1804499A AU 18044/99 A AU18044/99 A AU 18044/99A AU 1804499 A AU1804499 A AU 1804499A AU 1804499 A AU1804499 A AU 1804499A
Authority
AU
Australia
Prior art keywords
macrophage
intervention
inhibition
tumor growth
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU18044/99A
Inventor
Per Borgstrom
Mario A. Bourdon
Elena Deryugina
Pothapragada Srirama Rao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LA JOLLA INSTITUTE FOR EXPERIMENTAL MEDICINE
Original Assignee
La Jolla Inst For Experimental Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Inst For Experimental Medicine filed Critical La Jolla Inst For Experimental Medicine
Publication of AU1804499A publication Critical patent/AU1804499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU18044/99A 1997-12-05 1998-12-04 Inhibition of tumor growth by macrophage intervention Abandoned AU1804499A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6759197P 1997-12-05 1997-12-05
US60067591 1997-12-05
PCT/US1998/025791 WO1999029345A1 (en) 1997-12-05 1998-12-04 Inhibition of tumor growth by macrophage intervention

Publications (1)

Publication Number Publication Date
AU1804499A true AU1804499A (en) 1999-06-28

Family

ID=22077060

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18044/99A Abandoned AU1804499A (en) 1997-12-05 1998-12-04 Inhibition of tumor growth by macrophage intervention

Country Status (2)

Country Link
AU (1) AU1804499A (en)
WO (1) WO1999029345A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
CN1787837A (en) * 2002-11-15 2006-06-14 希龙公司 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
PL2311873T3 (en) 2004-01-07 2019-01-31 Novartis Vaccines And Diagnostics, Inc. M-csf-specific monoclonal antibody and uses thereof
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
RS58211B1 (en) 2010-05-04 2019-03-29 Five Prime Therapeutics Inc Antibodies that bind csf1r
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
RU2718751C2 (en) 2012-08-31 2020-04-14 Файв Прайм Терапьютикс, Инк. Methods of treating pathological conditions with antibodies which bind to the colony-stimulating factor 1 receptor (csf1r)
EP2941256B1 (en) 2012-12-30 2020-05-06 Carmel-Haifa University Economic Corporation Ltd Cd11b- low macrophages and conditioned media thereof for treating cancer and/or fibrosis
EP3157957A1 (en) 2014-06-23 2017-04-26 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SMT202100164T1 (en) 2014-10-29 2021-05-07 Bristol Myers Squibb Co Combination therapy for cancer
JP6797801B2 (en) 2014-12-22 2020-12-09 ファイヴ プライム セラピューティクス インク Anti-CSF1R antibody for treating PVNS
CA2980460A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
BR112020004879A2 (en) 2017-09-13 2020-09-15 Five Prime Therapeutics, Inc. methods to treat pancreatic cancer, to treat cancer and to determine the responsiveness of a subject with cancer
EP4093508A1 (en) 2020-01-24 2022-11-30 Pfizer Inc. Anti-e-selectin antibodies, compositions and methods of use

Also Published As

Publication number Publication date
WO1999029345A1 (en) 1999-06-17

Similar Documents

Publication Publication Date Title
AU1430699A (en) Production of propylene
AU4925799A (en) Production of propylene
AU5788396A (en) Methods of inhibition or killing of cancer cells
AU7168696A (en) Inhibitors of regulatory pathways
AU1804499A (en) Inhibition of tumor growth by macrophage intervention
AU4839999A (en) Tmprss2 is a tumor suppressor
AU4643699A (en) Angiopoietin-like growth factor sequences
AUPQ253199A0 (en) Non-prostanoid prostaglandin I2-agonist
AU6683496A (en) Use of griseofulvin for inhibiting the growth of cancers
AU5562999A (en) Methods of modulating of angiogenesis
AU4567199A (en) Autoinducer compounds
AUPQ137699A0 (en) Control of acidosis
AU3348295A (en) Improving the yield of plants
AU3348395A (en) Improving the yield of plants
AU4633397A (en) Synthesis of phosphorus compounds
AU5490099A (en) Manufacture of alpha-olefins
EP1001962B8 (en) Production of avermectin compounds
AU1709897A (en) Antimicrobial aurone derivatives
AU1933297A (en) Manufacture of elongate members
AU5126298A (en) Inhibition of crib-biting
AU6079396A (en) Para-hydroxyphenylacetic acid for reducing the repellency of insecticides
AU4632399A (en) Ester synthesis
AU5787399A (en) Novel targets of p53 regulatory activity
AU6926298A (en) Photoperiodic control of growth
AU5670898A (en) Manufacture of elongate members

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase